Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ …
MJ Pontecorvo, M Lu, SC Burnham, AE Schade… - JAMA …, 2022 - jamanetwork.com
Importance Plasma biomarkers of Alzheimer disease may be useful as minimally invasive
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of …
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of …
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
JR Sims, JA Zimmer, CD Evans, M Lu, P Ardayfio… - Jama, 2023 - jamanetwork.com
Importance There are limited efficacious treatments for Alzheimer disease. Objective To
assess efficacy and adverse events of donanemab, an antibody designed to clear brain …
assess efficacy and adverse events of donanemab, an antibody designed to clear brain …
Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial
S Shcherbinin, CD Evans, M Lu, SW Andersen… - JAMA …, 2022 - jamanetwork.com
Importance β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer
disease. Objective To perform post hoc analyses of amyloid reduction after donanemab …
disease. Objective To perform post hoc analyses of amyloid reduction after donanemab …
Donanemab in early Alzheimer's disease
MA Mintun, AC Lo, C Duggan Evans… - … England Journal of …, 2021 - Mass Medical Soc
Background A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ)
peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being …
peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being …
Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease
I Gueorguieva, BA Willis, L Chua… - Clinical …, 2023 - Wiley Online Library
Donanemab is an amyloid‐targeting therapy that resulted in robust amyloid plaque
reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the …
reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the …
Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
SL Lowe, BA Willis, A Hawdon… - … Research & Clinical …, 2021 - Wiley Online Library
Introduction This study explored the safety and tolerability features of donanemab
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
Donanemab for Alzheimer disease—who benefits and who is harmed?
Availability of safe and effective treatmentsfor Alzheimer disease is an urgent challenge
given the global shift toward an older population and increased risk of mild cognitive …
given the global shift toward an older population and increased risk of mild cognitive …
[HTML][HTML] Donanemab for Alzheimer's disease: a systematic review of clinical trials
Amyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the
clinical deterioration of Alzheimer's disease (AD). Recently, targeted-Aβ plaque reduction …
clinical deterioration of Alzheimer's disease (AD). Recently, targeted-Aβ plaque reduction …
[HTML][HTML] Donanemab (LY3002813) phase 1b study in Alzheimer's disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging
SL Lowe, C Duggan Evans, S Shcherbinin… - The journal of …, 2021 - Springer
Background Donanemab (LY3002813) is an IgG1 antibody directed at an N-terminal
pyroglutamate of amyloid beta epitope that is present only in brain amyloid plaques …
pyroglutamate of amyloid beta epitope that is present only in brain amyloid plaques …
Ushering in a new era of Alzheimer disease therapy
EW Widera, SA Brangman, NA Chin - JAMA, 2023 - jamanetwork.com
In June 2021, the US Food and Drug Administration (FDA) granted accelerated approval of
aducanumab, a monoclonal antibody against β-amyloid for treatment of early Alzheimer …
aducanumab, a monoclonal antibody against β-amyloid for treatment of early Alzheimer …
相关搜索
- donanemab treatment trailblazer alz
- alzheimer disease trailblazer alz
- donanemab treatment plasma biomarkers
- plasma biomarkers trailblazer alz
- donanemab treatment alzheimer disease
- alzheimer disease plasma biomarkers
- secondary analysis trailblazer alz
- secondary analysis plasma biomarkers
- donanemab treatment secondary analysis
- alzheimer disease secondary analysis
- donanemab treatment clinical outcomes
- clinical outcomes trailblazer alz
- donanemab treatment amyloid reduction
- amyloid reduction trailblazer alz
- donanemab treatment tau pathology
- tau pathology trailblazer alz